Pulmonary vascular resistance index (PVRI) and right ventricular end-systolic pressure (RVESP) may be significantly elevated in SC mice compared with WT animals (PVRI: 5.5 ± 1.9 vs 2.9 ± 0.28 mm Hg × min/μL/100 g; P = 0.004; RVESP: 23.1 ± 4.0 vs 18.9 ± 1.13 mm Hg; P = 0.03; Figure 4). Right ventricular cardiac output index (RVCOI) and right ventricular end-systolic elastance (RVEes) in SC mice were similar to WT animals (4.60 ± 0.51 vs 2.9 ± 0.85 mL/min/100 g; P = 0.10; and 0.58 ± 0.11 vs 0.89 ± 0.48 mm Hg/μL; P = 0.18; Figures 4 and 5). Treatment with ABH for 4 weeks restored PVRI and RVESP to levels similar to WT animals (PVRI: 3.4 ± 1.4 mm Hg × min/μL/100 g; RVESP: 20.1 ± 3.1 mm Hg; Figures 4 and 5). Treatment with ABH may elevate RVCOI in the SC animals compared with untreated SC animals, with no effect on RVEes (RVCOI: 5.1 ± 2.5 mL/min/100 g, P = 0.03 versus SC; RVEes: 0.79 ± 0.31 mm Hg/μL; Figures 4 and 5).
PWV, a measure of vascular stiffness, was greater in untreated SC mice than in WT controls. SC mice treated with ABH for 4 weeks had significantly reduced PWVs compared with untreated SC mice and were no different from WT controls (PWV in m/s: SC: 3.74 ± 0.54; WT: 3.25 ± 0.21 m/s; SC + ABH: 3.06 ± 0.31; P = 0.0009 by 1-way ANOVA; n = 20; Figure 6).
Loss of global NO and overall endothelial dysfunction is now well established in SCD. In this study, we show that arginase activity is significantly increased in SC mouse aorta compared with WT, whereas NO production is reduced. More importantly, we believe this is the first demonstration that arginase inhibition improves vascular function and reverses the vascular phenotype of SCD. These findings are in accordance with previous studies demonstrating not only arginase upregulation but more specifically upregulation of arginase II, as well as ornithine decarboxylase antizyme mRNA in platelets of SC patients.25,26 Moreover, we demonstrated an attenuated endothelial-dependent vasorelaxation response to ACh in SC mice.
Physiological changes in SC vasculopathy include increased pulmonary resistance, increased right ventricular systolic pressures, and greater PWV, suggesting stiffer vessels. These changes are recapitulated well in the SC mouse. One way to improve NO signaling downstream of NO in human subjects is through phosphodiesterase (PDE) inhibition. Interestingly, modest increases in plasma cyclic guanosine monophosphate and citrulline levels and improved pulmonary pressures, as well as 6-minute walk test distance, were observed in patients receiving sildenafil.9 A subsequent double-blind study in patients with pulmonary hypertension and decreased exercise tolerance that compared placebo with sildenafil was terminated after enrollment of 74 patients because there were more hospitalizations for pain in the sildenafil group, no difference in the 6-minute walk distance, and a trend to increased pulmonary hypertension in the sildenafil group.27 This is likely because the PDE5 inhibitor does not address the issue of eNOS uncoupling, and the high oxidative stress and low NO bioavailability in the vasculature remain unchanged. Indeed, if PDE5 inhibitors are to work, at least some bioavailable NO needs to be present to activate soluble guanylate cyclase. However, because these studies were performed in human subjects, only plasma levels of arginase were evaluated and endothelial arginase was not examined.8
In this study, treatment of SC mice with the arginase inhibitor ABH for 4 weeks decreased arginase activity and restored pulmonary pressures, resistance, and PWV to a level comparable with age-matched WT animals. Vasodilation in response to increasing concentrations of ACh in aortic rings was similar in all cohorts. This could, in part, have been because of the age of the mice used in this study, with older mice demonstrating impaired vasoreactivity. In addition, the increased PWV in these mice suggests that the in vivo environment with its fully functional mechanical and biochemical signaling mechanisms along with sickling cells may be required to observe alterations in vasoreactivity; a feature that is lost in the in vitro study. Finally, endothelial dysfunction may be dependent on the vascular bed. Indeed, to our knowledge, the only observation to date of endothelial dysfunction in this SC mouse model has been in the pulmonary circulation in vivo.28
Overall, these findings support previous studies that have proposed that arginase may be an important target in SCD-related vasculopathy and provide evidence for the use of arginase inhibitors for the treatment of SC vasculopathy.28,29 Although there are currently no specific arginase inhibitors available for human use, in 2007 it was demonstrated that chloroquine, a drug used as an antimalarial or antirheumatic medication, inhibits arginase in a dose-dependent manner including in sickle erythrocytes.30 Continued efforts to identify and characterize specific and selective arginase inhibitors are needed to further elucidate the therapeutic index of arginase in human subjects.
It is widely accepted that hemolytic rates and release of free hemoglobin into the circulation closely correlate with scavenging of NO. Two mechanisms can account for this loss of NO: first, cell-free hemoglobin can rapidly react with NO, and second, the released arginase 1 can consume L-arginine to further compromise substrate availability for NOS.29 However, given that arginase 2 also is upregulated in the endothelium of SC mice, there appears to be an endothelial contribution to SC vasculopathy that is independent from red blood cell hemolysis. Future studies will focus on separating the contribution of each arginase isoform (arginase 1 in the red blood cells versus arginase 2 in the endothelium) to the SC phenotype.
This study was performed in a rodent model with some experiments conducted ex vivo. The physiological experiments were performed with mice under general anesthesia with the chest cavity exposed to ambient pressure and air, and the lungs ventilated with positive pressure. This could have resulted in a change of pressures, flows, and volumes measurements and might not have been identical to awake and intact animals. Furthermore, placement of the catheter is difficult in small rodents and was done by visual recognition of pressure waveforms by a single provider without verification by other imaging modalities. Because methodologic variations may limit the generalizability of our results, we used a more stringent post hoc P value <0.01 as statistically significant. In the present study, it was not possible to delineate whether the detrimental effects of arginase in SCD are because of intracellular arginase 2 of the affected cells or because of the amount of arginase 1 liberated from the erythrocytes by hemolysis. These mechanisms can be distinguished by measuring endothelial and plasma NO and arginase in SC mice and their WT controls using pharmacological inhibition of each isoform.
Two important findings of this study are (1) increased arginase activity contributes to endothelial dysfunction, pulmonary hypertension, and vascular stiffness in transgenic SC mice; and (2) chronic treatment with an arginase inhibitor, ABH, attenuates systemic and pulmonary vascular dysfunction in transgenic SC mice. Thus, arginase is a potential novel therapeutic target in SC vasculopathy.
1. Kato GJ, Gladwin MT. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA 2008;300:2638–46.
2. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 2009;84:618–25.
3. Kassim AA, DeBaun MR. Sickle cell disease, vasculopathy, and therapeutics. Annu Rev Med 2013;64:451–66.
4. Crane GM, Bennett NE Jr. Priapism in sickle cell anemia: emerging mechanistic understanding and better preventative strategies. Anemia 2011;2011:297364.
5. Mosseri M, Bartlett-Pandite AN, Wenc K, Isner JM, Weinstein R. Inhibition of endothelium-dependent vasorelaxation by sickle erythrocytes. Am Heart J 1993;126:338–46.
6. Space SL, Lane PA, Pickett CK, Weil JV. Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium. Am J Hematol 2000;63:200–4.
7. White AR, Ryoo S, Li D, Champion HC, Steppan J, Wang D, Nyhan D, Shoukas AA, Hare JM, Berkowitz DE. Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension 2006;47:245–51.
8. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM Jr, Gladwin MT. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005;294:81–90.
9. Little JA, Hauser KP, Martyr SE, Harris A, Maric I, Morris CR, Suh JH, Taylor J, Castro O, Machado R, Kato G, Gladwin MT. Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol 2009;82:315–21.
10. Xiong Y, Fru MF, Yu Y, Montani JP, Ming XF, Yang Z. Long term exposure to L-arginine accelerates endothelial cell senescence through arginase-II and S6K1 signaling. Aging (Albany NY) 2014;6:369–79.
11. Potoka KP, Gladwin MT. Vasculopathy and pulmonary hypertension in sickle cell disease. Am J Physiol Lung Cell Mol Physiol 2015;308:L314–24.
12. Santhanam L, Lim HK, Lim HK, Miriel V, Brown T, Patel M, Balanson S, Ryoo S, Anderson M, Irani K, Khanday F, Di Costanzo L, Nyhan D, Hare JM, Christianson DW, Rivers R, Shoukas A, Berkowitz DE. Inducible NO synthase dependent S-nitrosylation and activation of arginase1 contribute to age-related endothelial dysfunction. Circ Res 2007;101:692–702.
13. Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G, Lim HK, Sohi J, Santhanam L, Soucy K, Tuday E, Baraban E, Ilies M, Gerstenblith G, Nyhan D, Shoukas A, Christianson DW, Alp NJ, Champion HC, Huso D, Berkowitz DE. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 2008;102:923–32.
14. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S, Burke S, Shoukas AA, Nyhan D, Champion HC, Hare JM. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003;108:2000–6.
15. Morris SM Jr. Arginine: beyond protein. Am J Clin Nutr 2006;83:508S–12S.
16. Santhanam L, Christianson DW, Nyhan D, Berkowitz DE. Arginase and vascular aging. J Appl Physiol (1985) 2008;105:1632–42.
17. Pászty C, Brion CM, Manci E, Witkowska HE, Stevens ME, Mohandas N, Rubin EM. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 1997;278:876–8.
18. Steppan J, Ryoo S, Schuleri KH, Gregg C, Hasan RK, White AR, Bugaj LJ, Khan M, Santhanam L, Nyhan D, Shoukas AA, Hare JM, Berkowitz DE. Arginase modulates myocardial contractility by a nitric oxide synthase 1-dependent mechanism. Proc Natl Acad Sci U S A 2006;103:4759–64.
19. Khan M, Steppan J, Schuleri KH, Schuleri K, Ryoo S, Tuday E, Bugaj L, Santhanam L, Berkowitz T, Nyhan D, Shoukas AA, Berkowitz DE. Upregulation of arginase-II contributes to decreased age-related myocardial contractile reserve. Eur J Appl Physiol 2012;112:2933–41.
20. Kim JH, Bugaj LJ, Oh YJ, Bivalacqua TJ, Ryoo S, Soucy KG, Santhanam L, Webb A, Camara A, Sikka G, Nyhan D, Shoukas AA, Ilies M, Christianson DW, Champion HC, Berkowitz DE. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J Appl Physiol (1985) 2009;107:1249–57.
21. Pacher P, Nagayama T, Mukhopadhyay P, Bátkai S, Kass DA. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 2008;3:1422–34.
22. Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA, Moens AL, Champion HC, Kass DA. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 2007;115:2159–67.
23. Steppan J, Tran H, Benjo AM, Pellakuru L, Barodka V, Ryoo S, Nyhan SM, Lussman C, Gupta G, White AR, Daher JP, Shoukas AA, Levine BD, Berkowitz DE. Alagebrium in combination with exercise ameliorates age-associated ventricular and vascular stiffness. Exp Gerontol 2012;47:565–72.
24. Hartley CJ, Taffet GE, Michael LH, Pham TT, Entman ML. Noninvasive determination of pulse-wave velocity in mice. Am J Physiol 1997;273:H494–500.
25. Kato GJ, McGowan V, Machado RF, Little JA, Taylor J IV, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006;107:2279–85.
26. Raghavachari N, Xu X, Harris A, Villagra J, Logun C, Barb J, Solomon MA, Suffredini AF, Danner RL, Kato G, Munson PJ, Morris SM Jr, Gladwin MT. Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. Circulation 2007;115:1551–62.
27. Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, Gibbs JS, Little JA, Schraufnagel DE, Krishnamurti L, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Onyekwere O, Castro OL, Sachdev V, Waclawiw MA, Woolson R, Goldsmith JC, Gladwin MT; walk-PHaSST Investigators and Patients. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 2011;118:855–64.
28. Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, Schimel DM, Cochard AE, Wang X, Schechter AN, Noguchi CT, Gladwin MT. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 2007;109:3088–98.
29. Morris CR, Gladwin MT, Kato GJ. Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med 2008;8:620–32.
30. Iyamu EW, Ekekezie C, Woods GM. In vitro evidence of the inhibitory capacity of chloroquine on arginase activity in sickle erythrocytes. Br J Haematol 2007;139:337–43.